Heart drug digoxin tested to slow ALS progression
NCT ID NCT07047209
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This phase 2a trial tests whether the heart medication digoxin is safe and can slow nerve damage in people with ALS. About 40 adults with early-stage ALS will take oral digoxin for 24 weeks. Researchers will monitor side effects and measure blood markers of nerve health to see if the drug has a protective effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MGH
Boston, Massachusetts, 02114, United States
-
Northwestern Universsity
Chicago, Illinois, 60611, United States
-
Nova Southeastern University
Davie, Florida, 33314, United States
Conditions
Explore the condition pages connected to this study.